

Fibroblast Growth Factors (FGFs) Market - 2024-2033

<https://marketpublishers.com/r/F8834F696780EN.html>

Date: January 2026

Pages: 220

Price: US\$ 2,999.00 (Single User License)

ID: F8834F696780EN

Abstracts

The Fibroblast Growth Factors (FGFs) Market was valued at US\$ 303.75 million in 2024 and is anticipated to reach US\$ 598.06 million by 2033, at a CAGR of 0.082 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Fibroblast Growth Factors (FGFs) Market.

This report delivers a comprehensive overview of the Fibroblast Growth Factors (FGFs) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Fibroblast Growth Factors (FGFs) Market. The Fibroblast Growth Factors (FGFs) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Fibroblast Growth Factors (FGFs) Market Scope:

By Type

Palifermin

Erdafitinib

Infigratinib

Futibatinib

Others

By Application

Oncology

Hematology

Wound Healing

Dermatology

Cardiovascular Disease

Bone Disorders

Musculoskeletal Disorders

Tissue Regeneration

Others

By End-User

Pharmaceutical and Biotechnology Companies

Research Centers & Academic Institutes

Others

Key Players

Amgen Inc.

Thermo Fisher Scientific Inc.

Johnson & Johnson

Tyra Biosciences, Inc.

Eisai Co., Ltd.

Alnylam Pharmaceuticals, Inc.

Relay Therapeutics

Abbisko Therapeutics Co, Ltd

BridgeBio Pharma, Inc.

Incyte.

TAIHO PHARMACEUTICAL CO., LTD.

Major Highlights

This report delivers a comprehensive overview of the Fibroblast Growth Factors (FGFs) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Fibroblast Growth Factors (FGFs) Market. The Fibroblast Growth Factors (FGFs) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing

strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Application
- 3.3. Snippet by End-User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Advancements in Research and Development
 - 4.1.1.2. XX
 - 4.1.2. Restraints
 - 4.1.2.1. Stringent Regulatory Requirements
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 5.1. Market Leaders and Pioneers
- 5.2. Emerging Pioneers and Prominent Players
- 5.3. Established leaders with largest largest-selling Brand
- 5.4. Market leaders with established Product
- 5.5. CXO Perspectives
- 5.6. Latest Developments and Breakthroughs
- 5.7. Case Studies/Ongoing Research
- 5.8. Regulatory and Reimbursement Landscape
- 5.9. North America
- 5.10. Europe

- 5.11. Asia Pacific
- 5.12. Latin America
- 5.13. Middle East & Africa
- 5.14. Porter's Five Force Analysis
- 5.15. Supply Chain Analysis
- 5.16. Patent Analysis
- 5.17. SWOT Analysis
- 5.18. Unmet Needs and Gaps
- 5.19. Recommended Strategies for Market Entry and Expansion
- 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 5.21. Pricing Analysis and Price Dynamics
- 5.22. Key Opinion Leaders

6. BY TYPE

- 6.1. Introduction
 - 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
 - 6.1.2. Market Attractiveness Index, By Type
- 6.2. Palifermin*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Erdafitinib
- 6.4. Infigratinib
- 6.5. Futibatinib
- 6.6. Others

7. BY APPLICATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 7.1.2. Market Attractiveness Index, By Application
- 7.2. Oncology*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Hematology
- 7.4. Wound Healing
- 7.5. Dermatology
- 7.6. Cardiovascular Disease
- 7.7. Bone Disorders

- 7.8. Musculoskeletal Disorders
- 7.9. Tissue Regeneration
- 7.10. Others

8. BY END-USER

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 8.1.2. Market Attractiveness Index, By End-User
- 8.2. Pharmaceutical and Biotechnology Companies*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Research Centers & Academic Institutes
- 8.4. Others

9. BY REGION

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
 - 9.2.1. Introduction
 - 9.2.2. Key Region-Specific Dynamics
 - 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.2.6.1. U.S.
 - 9.2.6.2. Canada
 - 9.2.6.3. Mexico
- 9.3. Europe
 - 9.3.1. Introduction
 - 9.3.2. Key Region-Specific Dynamics
 - 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.3.6.1. Germany
 - 9.3.6.2. U.K.

9.3.6.3. France

9.3.6.4. Spain

9.3.6.5. Italy

9.3.6.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. China

9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. South Korea

9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Amgen Inc.*

11.1.1. Company Overview

11.1.2. Product Portfolio

11.1.2.1. Product Description

11.1.2.2. Product Key Performance Indicators (KPIs)

11.1.2.3. Historic and Forecasted Product Sales

11.1.2.4. Product Sales Volume

11.1.3. Financial Overview

11.1.3.1. Company Revenue's

11.1.3.2. Geographical Revenue Shares

11.1.3.3. Revenue Forecasts

11.1.4. Key Developments

11.1.4.1. Mergers & Acquisitions

11.1.4.2. Key Product Development Activities

11.1.4.3. Regulatory Approvals etc.

11.1.5. SWOT Analysis

11.2. Thermo Fisher Scientific Inc.

11.3. Johnson & Johnson

11.4. Tyra Biosciences, Inc.

11.5. Eisai Co., Ltd.

11.6. Alnylam Pharmaceuticals, Inc.

11.7. Relay Therapeutics

11.8. Abbisko Therapeutics Co, Ltd

11.9. BridgeBio Pharma, Inc.

11.10. Incyte.

11.11. TAIHO PHARMACEUTICAL CO., LTD. (*LIST NOT EXHAUSTIVE)

12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

I would like to order

Product name: Fibroblast Growth Factors (FGFs) Market - 2024-2033

Product link: <https://marketpublishers.com/r/F8834F696780EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F8834F696780EN.html>